Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
Valuation and Earnings
This table compares Phio Pharmaceuticals and Unicycive Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Phio Pharmaceuticals | N/A | N/A | -$8.70 million | ($1.38) | -0.78 |
| Unicycive Therapeutics | N/A | N/A | -$26.56 million | ($2.21) | -2.53 |
Profitability
This table compares Phio Pharmaceuticals and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Phio Pharmaceuticals | N/A | -77.34% | -70.87% |
| Unicycive Therapeutics | N/A | -134.69% | -84.51% |
Institutional and Insider Ownership
57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Phio Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for Phio Pharmaceuticals and Unicycive Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Phio Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Unicycive Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,204.75%. Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 289.58%. Given Phio Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Phio Pharmaceuticals is more favorable than Unicycive Therapeutics.
Summary
Phio Pharmaceuticals beats Unicycive Therapeutics on 7 of the 11 factors compared between the two stocks.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
